PeptideGLP-1GLP-1 Agonist
Survodutide
Dual agonist (GLP-1 / glucagon)
Typical dose
0.3–6 mg weekly
once weekly · SubQ · titrate up
Half-life
~weekly dosing
What is Survodutide?
GLP-1/glucagon receptor dual agonist; emerging metabolic compound.
How Survodutide works
Dual GLP-1/glucagon agonist — GLP-1 for appetite/satiety, glucagon emphasized for hepatic/metabolic effect (fatty liver).
Benefits & uses
- Weight loss
- Appetite reduction
- Notable liver benefit (MASH program)
- Glucagon-driven metabolic effect
Common uses: Fat loss / obesity, fatty liver disease (MASH), metabolic health.
Survodutide dosage
- Typical dose
- Typical: start ~0.3–0.6 mg/week SubQ, titrate up toward 3–6 mg/week. Once weekly.
Survodutide half-life
~weekly dosing
Survodutide side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Heart-rate increase
Warnings & monitoring
- Titrate slowly for GI tolerance
- Glucagon component can raise heart rate
- Class GLP-1 risks apply
- Thyroid C-cell class caution
- Not for pregnancy
Preparation & storage
- Preparation
- Mix a 10 mg vial with 2 mL bac water → 5 mg/mL. A 0.6 mg dose = 0.12 mL = 12 units. Start low, titrate up.
- Reconstitution
- Reconstitute a 10 mg vial with 2 mL BAC water → 5 mg/mL. A 0.6 mg dose = 0.12 mL = 12 units on a U-100 syringe.
Track Survodutide in Protokol.
Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.
More GLP-1 Agonist
- CagrilintideLong-acting amylin analog used for appetite/weight management, often combined…
- CagriSema (Cagrilintide + Semaglutide)Fixed blend of cagrilintide (amylin) and semaglutide (GLP-1).
- GLP-1 (Native)Native glucagon-like peptide-1 — the body's own incretin hormone that the…
- LiraglutideOlder daily GLP-1 agonist (shorter half-life than weekly agents).
- MazdutideGLP-1/glucagon dual agonist; emerging weight-loss and metabolic peptide.
- Reta+Cagri BlendFixed blend of retatrutide and cagrilintide.